Short-course vaginal cuff brachytherapy (VCB) is noninferior to standard regimens for short-term quality of life in people ...
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
Endometrial cancer isn’t talked about much as much as it should be. It’s the most common cancer of the female reproductive organs in the U.S. and more than 69,000 people in the U.S. are diagnosed with ...
Endometriosis, a prevalent gynecological condition, is characterized by the growth of endometrial-like tissues outside the ...
GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...
GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...
Jemperli (Dostarlimab): GlaxoSmithKline Jemperli (dostarlimab) is an anti-PD-1 monoclonal antibody developed by GlaxoSmithKline that has been approved for use in advanced or recurrent endometrial ...
The EMA’s acceptance of the prefilled syringe follows the European Commission’s (EC) approval of GSK’s Jemperli, combined with chemotherapy for the treatment of advanced or recurrent endometrial ...
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China Severe endometrial injuries may cause thin endometrium and intrauterine adhesion in women which can result in ...
Used to treat advanced or recurrent endometrial cancer, Jemperli Dostarlimab, presents an opportunity to enhance the immune response against cancer cells when combined with chemotherapy. Get Your Free ...